Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1555-1559

  da Cunha Júnior, Edézio Ferreira ^a   Pacienza Lima, Wallace ^b   Ribeiro, Grazielle Alves ^a   Netto, Chaquip Daher ^b   do Canto Cavalheiro, Marilene Marcuzzo ^a   da Silva, Alcides José Monteiro ^b   Costa, Paulo Roberto Ribeiro ^b   Rossi Bergmann, Bartira ^b   Torres Santos, Eduardo Caio ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiparasitics; Chemotherapy; Pterocarpan

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILEISHMANIAL AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; LQB 118; NAPHTHOQUINONE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; IC 50; IN VIVO STUDY; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; SKIN LEISHMANIASIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ALANINE TRANSAMINASE; ANIMALS; ANTIPROTOZOAL AGENTS; ASPARTATE AMINOTRANSFERASES; CREATININE; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; INHIBITORY CONCENTRATION 50; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LIVER; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; PTEROCARPANS; RODENT DISEASES; SERUM; TREATMENT OUTCOME;

EID: 79958841686     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr158     Document Type: Article

References (10)

1. Santos DO, Coutinho CE, Madeira MF et al. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 2008; 103: 1-10.
2. Salem MM, Werbovetz KA. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr Med Chem 2006; 13: 2571-98.
3. Murray HW, Hariprashad J. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents Chemother 1996; 40: 586-7.
4. Netto CD, Santos ES, Castro CP et al. (+/2)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives: cytotoxic effect on human leukemia cell lines. Eur J Med Chem 2009; 44: 920-5.
5. Netto CD, da Silva AJ, Salustiano EJ et al. New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-α modulation in human PBMC cells. Bioorg Med Chem 2010; 18: 1610-6.
6. Mendez S, Traslavina R, Hinchman M et al. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 2009; 53: 5114-21.
7. da Silva AJM, Netto CD, Pacienza-Lima W et al. Antitumoral, antileishmanial and antimalarial activity of pentacyclic 1,4-naphthoquinone derivatives. J Braz Chem Soc 2009; 20: 176-82.
8. Al-Abdely HM, Graybill JR, Loebenberg D et al. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 1999; 43: 2910-4.
9. Gonçalves GS, Fernandes AP, Souza RC et al. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 2005; 93: 161-7.
10. Hao H, Wang G, Cui N et al. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 2007; 8: 137-49.